## Christian Fadeuilhe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/393105/publications.pdf

Version: 2024-02-01

1040056 1058476 16 272 9 14 citations h-index g-index papers 18 18 18 450 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Shared genetic background between children and adults with attention deficit/hyperactivity disorder. Neuropsychopharmacology, 2020, 45, 1617-1626.	5.4	72
2	Sleep in adults with autism spectrum disorder and attention deficit/hyperactivity disorder: A systematic review and meta-analysis. European Neuropsychopharmacology, 2020, 38, 1-24.	0.7	33
3	Epigenetic signature for attention-deficit/hyperactivity disorder: identification of miR-26b-5p, miR-185-5p, and miR-191-5p as potential biomarkers in peripheral blood mononuclear cells. Neuropsychopharmacology, 2019, 44, 890-897.	5.4	31
4	Genetic overlap and causality between substance use disorder and ⟨scp⟩attentionâ€deficit⟨ scp⟩ and hyperactivity disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2021, 186, 140-150.	1.7	25
5	Gut microbiota signature in treatment-na $ ilde{A}^-$ ve attention-deficit/hyperactivity disorder. Translational Psychiatry, 2021, 11, 382.	4.8	25
6	Insomnia Disorder in Adult Attention-Deficit/Hyperactivity Disorder Patients: Clinical, Comorbidity, and Treatment Correlates. Frontiers in Psychiatry, 2021, 12, 663889.	2.6	16
7	Effectiveness of Inhaled Loxapine in Dual-Diagnosis Patients: A Case Series. Clinical Neuropharmacology, 2016, 39, 206-209.	0.7	14
8	Epigenome-wide association study of attention-deficit/hyperactivity disorder in adults. Translational Psychiatry, 2020, 10, 199.	4.8	14
9	Association Between Vitamin D Status and Schizophrenia. Journal of Nervous and Mental Disease, 2017, 205, 409-412.	1.0	10
10	The Relationship Between Neuropsychological Deficits and Emotional Lability in Adults With ADHD. Journal of Attention Disorders, 2019, 23, 1514-1525.	2.6	9
11	Transcriptome profiling in adult attention-deficit hyperactivity disorder. European Neuropsychopharmacology, 2020, 41, 160-166.	0.7	7
12	La Atenci $\tilde{A}^3$ n a las Necesidades en Salud Mental de los Profesionales Sanitarios durante la COVID-19. Clinica Y Salud, 2021, 32, 119-128.	0.8	7
13	Inhaled Loxapine for Agitation in Intoxicated Patients: A Case Series. Clinical Neuropharmacology, 2017, 40, 281-285.	0.7	6
14	Buprenorphine-Naloxone Treatment in Physicians and Nurses with Opioid Dependence. Substance Abuse, 2015, 36, 138-140.	2.3	3
15	Evidence For Association Of Genetic Variants In Pri-Mir-34B/C And Abnormal MIR-34C Expression With Attention-Deficit And Hyperactivity Disorder. European Neuropsychopharmacology, 2017, 27, S433-S434.	0.7	0
16	F5EPIGENETIC SIGNATURE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER: IDENTIFICATION OF MIR-23A-5P, MIR-26B-5P, MIR-185-5P AND MIR-191-5P AS A POTENTIAL BIOMARKER IN PERIPHERAL BLOOD MONONUCLEAR CELLS. European Neuropsychopharmacology, 2019, 29, S1112.	0.7	0